Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.23
EGLT's Cash to Debt is ranked lower than
76% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. EGLT: 1.23 )
Ranked among companies with meaningful Cash to Debt only.
EGLT' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 1.23
Equity to Asset 0.19
EGLT's Equity to Asset is ranked lower than
88% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
EGLT' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.5 Max: 0.85
Current: 0.19
0.19
0.85
F-Score: 3
Z-Score: -2.36
M-Score: 2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -227.83
EGLT's Operating margin (%) is ranked lower than
60% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. EGLT: -227.83 )
Ranked among companies with meaningful Operating margin (%) only.
EGLT' s Operating margin (%) Range Over the Past 10 Years
Min: -1934.17  Med: -692.37 Max: -227.83
Current: -227.83
-1934.17
-227.83
Net-margin (%) -251.51
EGLT's Net-margin (%) is ranked lower than
62% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. EGLT: -251.51 )
Ranked among companies with meaningful Net-margin (%) only.
EGLT' s Net-margin (%) Range Over the Past 10 Years
Min: -2250.73  Med: -740.47 Max: -251.51
Current: -251.51
-2250.73
-251.51
ROE (%) -113.60
EGLT's ROE (%) is ranked lower than
83% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. EGLT: -113.60 )
Ranked among companies with meaningful ROE (%) only.
EGLT' s ROE (%) Range Over the Past 10 Years
Min: -444.79  Med: -265.8 Max: -86.8
Current: -113.6
-444.79
-86.8
ROA (%) -48.16
EGLT's ROA (%) is ranked lower than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. EGLT: -48.16 )
Ranked among companies with meaningful ROA (%) only.
EGLT' s ROA (%) Range Over the Past 10 Years
Min: -307.77  Med: -140.37 Max: -48.16
Current: -48.16
-307.77
-48.16
ROC (Joel Greenblatt) (%) -701.75
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. EGLT: -701.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EGLT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1093.04  Med: -854.74 Max: -672.52
Current: -701.75
-1093.04
-672.52
GuruFocus has detected 4 Warning Signs with Egalet Corp $EGLT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
Q1 2016

EGLT Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VBIV, NAS:VVUS, NAS:KIN, NAS:RGLS, NAS:EVGN, NAS:ATHX, NAS:ADVM, NAS:AUPH, NAS:MRTX, NAS:KURA, NAS:ALBO, NAS:GLYC, OTCPK:RNUGF, NAS:CNAT, NAS:GNCA, OTCPK:HPPI, NAS:REPH, NAS:ARWR, NAS:VBLT, OTCPK:MTNB » details
Egalet Corp is a specialty pharmaceutical company. The Company is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications.

Ratios

vs
industry
vs
history
P/B 5.29
EGLT's P/B is ranked lower than
65% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. EGLT: 5.29 )
Ranked among companies with meaningful P/B only.
EGLT' s P/B Range Over the Past 10 Years
Min: 1.41  Med: 3.33 Max: 9.79
Current: 5.29
1.41
9.79
P/S 3.73
EGLT's P/S is ranked higher than
77% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. EGLT: 3.73 )
Ranked among companies with meaningful P/S only.
EGLT' s P/S Range Over the Past 10 Years
Min: 3.42  Med: 52.36 Max: 670
Current: 3.73
3.42
670
Current Ratio 4.36
EGLT's Current Ratio is ranked higher than
52% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. EGLT: 4.36 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.6 Max: 29.19
Current: 4.36
0.86
29.19
Quick Ratio 4.30
EGLT's Quick Ratio is ranked higher than
53% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. EGLT: 4.30 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.53 Max: 29.19
Current: 4.3
0.86
29.19
Days Inventory 150.95
EGLT's Days Inventory is ranked lower than
58% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. EGLT: 150.95 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 102.49 Max: 150.95
Current: 150.95
102.49
150.95
Days Sales Outstanding 46.97
EGLT's Days Sales Outstanding is ranked higher than
63% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. EGLT: 46.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 81.92 Max: 321.28
Current: 46.97
4.72
321.28
Days Payable 400.93
EGLT's Days Payable is ranked higher than
92% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. EGLT: 400.93 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 400.93  Med: 827.64 Max: 827.64
Current: 400.93
400.93
827.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 107.20
EGLT's Price/Net Current Asset Value is ranked lower than
98% of the 633 Companies
in the Global Biotechnology industry.

( Industry Median: 5.63 vs. EGLT: 107.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 4.13 Max: 152.2
Current: 107.2
2.09
152.2
Price/Tangible Book 8.12
EGLT's Price/Tangible Book is ranked lower than
71% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. EGLT: 8.12 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 3.51 Max: 14.68
Current: 8.12
1.9
14.68
Price/Median PS Value 0.07
EGLT's Price/Median PS Value is ranked higher than
98% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. EGLT: 0.07 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 1.04 Max: 9.92
Current: 0.07
0.07
9.92
Earnings Yield (Greenblatt) (%) -66.13
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. EGLT: -66.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -318.41  Med: 0 Max: 0
Current: -66.13
-318.41
0

More Statistics

Revenue (TTM) (Mil) $30.23
EPS (TTM) $ -2.96
Short Percentage of Float54.41%
52-Week Range $4.34 - 10.00
Shares Outstanding (Mil)25.19

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 37 57 86
EPS ($) -3.63 -3.10 -2.40 -1.40
EPS w/o NRI ($) -3.63 -3.10 -2.40 -1.40
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jan 18 2017
Egalet Closes Second Tranche of $80 Million Secured Debt Financing Jan 18 2017
FDA approves Teva's abuse-deterrent painkiller Jan 18 2017
SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Egalet Corporation and Encourages... Jan 13 2017
EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in... Jan 13 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Egalet Corporation and Advises... Jan 12 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations... Jan 12 2017
EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Jan 12 2017
Latest Reports on Egalet and Illumina as the NASDAQ Continues to Hit Record Highs Jan 11 2017
FDA Clears Egalet's Long-Acting Opioid Painkiller Jan 10 2017
Egalet Corp (EGLT) Gets Approval But Fails On Labelling, Here’s What’s Next Jan 10 2017
Egalet painkiller wins FDA approval but label disappoints Jan 09 2017
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Jan 09 2017
FDA approves Wayne firm's tamper-resistant opioid medicine Jan 09 2017
Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine... Jan 09 2017
Egalet's long-acting opioid painkiller Arymo wins FDA approval Jan 09 2017
Three Companies Set To Benefit From The 21st Century Cures Act: Who And Why Dec 20 2016
Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress Dec 19 2016
Company News for December 19, 2016 Dec 19 2016
Analyst Sees Nearly 100% Upside In Egalet Following Latest Clinical Data Dec 19 2016
Blog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002 Dec 19 2016
Egalet Announces Positive Top-Line Results from an Intranasal Human Abuse Potential Study of... Dec 16 2016
Egalet Reports Third Quarter 2016 Financial Results Nov 04 2016
Egalet to Present at Abuse-Deterrent Formulations and Investor Conferences this Fall Oct 28 2016
Egalet to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results on... Oct 20 2016
Egalet Notified that FDA Will Not Meet PDUFA Goal Data for ARYMO ER Oct 13 2016
Egalet Appoints Patrick Shea as Chief Commercial Officer Sep 19 2016
Egalet Announces OXAYDO® Demonstrates Bioequivalence at 15 mg Dose Sep 12 2016
Egalet Announces Category 1 Abuse-Deterrent Data Demonstrating OXAYDO® Resists Syringeability Sep 08 2016
Egalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO™ ER (Morphine... Aug 04 2016
Egalet to Present at Cantor Fitzgerald Healthcare Conference Jul 07 2016
Egalet Announces FDA Advisory Committee Meeting will Take Place August 4, 2016 for Lead... Jun 28 2016
Data Presented at College on Problems of Drug Dependence (CPDD) Meeting Show Egalet's Guardian... Jun 13 2016
Egalet President and CEO Bob Radie Named EY Entrepreneur of the Year® Jun 10 2016
Egalet Settles Patent Litigations with Purdue Pharma May 23 2016
Egalet Human Abuse Potential Data at American Pain Society Annual Meeting Demonstrates Significantly... May 12 2016
Egalet Reports First Quarter 2016 Financial Results May 10 2016
Egalet Announces Scientific Presentations at American Pain Society Meeting May 05 2016
Egalet to Present at Upcoming Investor Conferences this Spring May 04 2016
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results on May... Apr 27 2016
Egalet Announces Upcoming Opportunities for Community to Dispose of Prescription Medications Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)